This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What Does Nu Skin's Mavely Sale Mean for Its Long-Term Strategy?
by Zacks Equity Research
NUS' subsidiary has sold its Mavely affiliate marketing platform to Later for nearly $250 million, boosting innovation and resources.
Nu Skin Stock Sinks 40% in Six Months: Hold Steady or Time to Exit?
by Zacks Equity Research
Nu Skin is struggling with a difficult macroeconomic landscape, volatile currency movements and pressures in the direct selling industry.
Nu Skin Q3 Earnings & Sales Miss Estimates, 2024 Guidance Cut
by Zacks Equity Research
NUS' Q3 results show lower earnings and net sales amid macroeconomic pressures and challenges in the direct selling industry. Management lowers 2024 view.
Nu Skin Enterprises (NUS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -15% and 3.14%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Coty, Helen of Troy, European Wax Center and Nu Skin
by Zacks Equity Research
Coty, Helen of Troy, European Wax Center and Nu Skin are part of the Zacks Industry Outlook article.
E.l.f. Beauty (ELF) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
e.l.f. Beauty (ELF) delivered earnings and revenue surprises of 71.11% and 3.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
4 Cosmetics Stocks Worth Watching Despite Industry Challenges
by Ansuiya Mohta
The Zacks Cosmetics industry is navigating a tough shopping environment. Nevertheless, COTY, Helen of Troy, European Wax Center and Nu Skin are leveraging innovations.
Nu Skin's Q3 Earnings Coming Up: Here's What You Should Know
by Zacks Equity Research
NUS' Q3 results are likely to reflect the impacts of macroeconomic hurdles on consumer spending and customer acquisition.
Nu Skin Navigates Growth With Innovation Amid Industry Challenges
by Zacks Equity Research
NUS drives growth through strategic initiatives, innovative product launches like MYND360 and the expanding Rhyz business amid macroeconomic woes.
NUS Stock Trading Below 200 & 50-Day SMA: What Should You Do Now?
by Zacks Equity Research
Nu Skin is encountering persistent macroeconomic obstacles, weighing on consumer spending and customer acquisition.
Nu Skin Trading Near 52-Week Low: Should You Buy or Sell NUS Stock?
by Zacks Equity Research
Nu Skin is facing macroeconomic difficulties and a slow-moving direct-selling market. Foreign currency headwinds are also weighing on NUS.
NUS Stock Hurt by Customer Acquisition Challenges: How to Play Ahead?
by Zacks Equity Research
Nu Skin encounters macroeconomic challenges related to volatile consumer spending and strong currency headwinds.
Nu Skin (NUS) Down 28% in 3 Months: What's the Next Best Move?
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds, which have been weighing on consumer spending and customer acquisition. Strong currency headwinds are also playing foul.
Are Options Traders Betting on a Big Move in Nu Skin (NUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nu Skin (NUS) stock based on the movements in the options market lately.
Nu Skin (NUS) Trims FY24 View Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2024 results reflect lower earnings and net sales amid a dynamic macro-environment. Management lowers the 2024 guidance range.
Nu Skin Enterprises (NUS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 16.67% and 2.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Set to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Nu Skin's (NUS) Q2 results are likely to reflect the impacts of macroeconomic challenges, including inflation and adverse currency fluctuations.
Nu Skin (NUS) Navigates a Tough Landscape on Growth Strategies
by Zacks Equity Research
Nu Skin (NUS) has been dealing with challenges related to customer and affiliate acquisition. However, product launches, technological advancements and strength in the Rhyz business bode well.
Nu Skin (NUS) Troubled by Customer Acquisition Challenges
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds across most regions, which has affected customer and affiliate acquisition.
Nu Skin (NUS) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Q1 Earnings Beat, Revenues Hurt by Currency Woes
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 results reflect challenges related to volatile currency movements, while cost-management efforts work well.
Nu Skin Enterprises (NUS) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 80% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Q1 Earnings Coming Up: Factors to Consider
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations are a concern.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Why Is Inter Parfums (IPAR) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.